» Articles » PMID: 24764593

Combination Therapy with Pegylated Interferon Plus Ribavirin in the Treatment of Hepatitis C Virus-related Thrombocytopenia

Overview
Specialty Pharmacology
Date 2014 Apr 26
PMID 24764593
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Isolated thrombocytopenia is a common manifestation of hepatitis C virus (HCV) infection. There is no established treatment modality for this condition. The efficacy of standard interferon (IFN) monotherapy has been reported in some studies. The major disadvantage of this treatment is the high rate of recurrence due to viral breakthrough during the first 12 weeks of treatment. Pegylated IFNs are now the standard regimen for chronic hepatic disease due to HCV infection. However, due to a lack of evidence, pegylated IFNs are not widely used for HCV-related isolated thrombocytopenia.

Objective: The aim of this report was to present the case of a male patientwith severe symptomatic thrombocytopenia due to HCV infection.

Methods: Thrombocytopenia was treated with pegylated IFN plus ribavirin.

Results: Although standard IFN monotherapy failed to achieve virologic and hematologic improvement, therapy with pegylated IFN alfa-2a plus ribavirin was associated with both virologic and hematologic improvement without any significant adverse effects.

Conclusions: Pegylated IFN plus ribavirin was effective in this patient for thetreatment of HCV-related thrombocytopenia. However, further research is needed to define the response rate in different patient populations.

References
1.
Hamaia S, Li C, Allain J . The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood. 2001; 98(8):2293-300. DOI: 10.1182/blood.v98.8.2293. View

2.
Ramos-Casals M, Garcia-Carrasco M, Lopez-Medrano F, Trejo O, Forns X, Lopez-Guillermo A . Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinical description of 35 cases. Medicine (Baltimore). 2003; 82(2):87-96. DOI: 10.1097/00005792-200303000-00003. View

3.
Gumber S, Chopra S . Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med. 1995; 123(8):615-20. DOI: 10.7326/0003-4819-123-8-199510150-00008. View

4.
Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View

5.
Manns M, McHutchison J, Gordon S, Rustgi V, Shiffman M, Reindollar R . Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. DOI: 10.1016/s0140-6736(01)06102-5. View